BioCentury
ARTICLE | Clinical News

APTO-253: Phase Ib hold

December 14, 2015 8:00 AM UTC

FDA placed a clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The hold follows a voluntary suspension of dosing and preliminary review that ...